The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
35 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $14,557,545 in first-year total cost, median $395,248.
Most frequent study sections
- Special Emphasis Panel[ZRG1 ETTN-S (14)]6
- Special Emphasis Panel[ZRG1 ETTN-C (10)]4
- Special Emphasis Panel[ZRG1 ETTN-H (11)]4
- Special Emphasis Panel[ZRG1 RPHB-Y (12)]4
- Special Emphasis Panel[ZRG1 AN-P (11)]3
Most frequent institutions
- REGENNOVA, INC.2
- ACEPRE, LLC1
- ACTIVITY RHYTHM SOLUTIONS CORPORATION1
- ADAPT DESIGN WORKS, LLC1
- AROMHA, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | VoiceLove: An App-Based COMmunication Tool Designed to Address DeliriUm and Improve Family ENgagement and PatIent/Family SatisfaCtion in CriticAlly Ill PaTiEnts (COMMUNICATE)1R42AG080891-01 | ELY, E WESLEY | VOICELOVE LLC, NY | $506,500 | ZRG1 |
| 2023 | A Therapeutic Role for Apolipoprotein-E in the Germ Theory of Alzheimer's Dementia1R41AG078111-01A1 | VITEK, MICHAEL P. | REGENNOVA, INC., NC | $500,000 | ZRG1 |
| 2023 | Novel Combinations of Natural Product Compounds for Treatment of Alzheimer Disease and Related Dementias1R41AG080957-01 | CHANG, RUIRONALDSON, PATRICK THOMASWANG, WEI | PATH BIOTECH, LLC, AZ | $499,996 | ZRG1 |
| 2023 | Discovery of therapeutic nanobodies targeting brain TNF-α for the treatment of Alzheimer Disease1R41AG080864-01A1 | D'ADAMIO, LUCIANOFIORITI, LUANA | NANONEWRON LLC, NJ | $499,828 | ZRG1 |
| 2023 | SMALL MOLECULE THERAPEUTIC FOR ALZHEIMER'S DISEASE1R41AG080914-01A1 | WITT, KEN | SOMATOLYNK, INC., IL | $499,592 | ZRG1 |
| 2023 | Developing of a computer-based multimodal mind and body approach for mild cognitive decline1R41AG082591-01 | KONG, JIAN | BRAIN THRIVE TECHNOLOGY LLC, MA | $498,094 | ZRG1 |
| 2023 | Novel multi-sensing seat cover system for prevention of sitting-related pressure injuries in individuals with Alzheimer's disease or related dementias1R41AG080965-01 | MCGEE, COREY WWUDLICK, ROB | ADAPT DESIGN WORKS, LLC, MN | $496,520 | ZRG1 |
| 2023 | A Novel Pharmacological Inhibitor of Adenylyl Cyclase Type 5 to Treat Alzheimer's Disease1R41AG080990-01 | VATNER, STEPHEN F | VASADE BIOSCIENCES, INC., NJ | $252,130 | ZRG1 |
| 2023 | Mosaic Display of Multivalent Tau and A-Beta peptides on Immunogenic SNAP Liposomes1R41AG082620-01 | DAI, CHUNLINGHUANG, WEI-CHIAO | POP BIOTECHNOLOGIES, INC, NY | $248,855 | ZRG1 |
| 2023 | Noninvasive sleep enhancement and behavior monitoring technologies for Alzheimer's model mice1R41AG082600-01 | O'HARA, BRUCE FREDERICK | SIGNAL SOLUTIONS, LLC, KY | $180,612 | ZRG1 |
| 2023 | Optimizing brain penetrance of caspase-6 inhibitors to treat neurodegenerative diseases1R41AG078036-01A1 | ARKIN, MICHELLECANAN, STACIERENSLO, ADAM R | ELGIA THERAPEUTICS, INC., CA | $180,375 | ZRG1 |
| 2022 | Therapeutic Reduction of Cerebral Amyloid Angiopathy Pathologies in ADRD1R41NS127666-01A1 | VITEK, MICHAEL P. | REGENNOVA, INC., NC | $499,900 | ZRG1 |
| 2022 | Jigsawdio: an AudioVisual Jigsaw Puzzle for People with Alzheimer's Disease and Alzheimer's-Disease-Related Dementias1R41AG079736-01 | YOUNG, AMY | CALLAHAN-YOUNG LLC, NC | $499,670 | ZRG1 |
| 2022 | APOE-targeted therapy for precision medicine in late onset Alzheimer's disease: A novel epigenome editing approach for downregulation of APOEe4 expression1R41AG077992-01 | HAMM, ELAINE | CLAIRIGENE, LLC, NC | $492,903 | ZRG1 |
| 2022 | Using siRNAs against tau circular RNAs as a rational therapy for Alzheimer's disease1R41AG078096-01 | STAMM, STEFAN | CIRCCURE CORPORATION, KY | $395,248 | ZRG1 |
| 2022 | Development of a lead candidate for the treatment of Alzheimer's disease1R41AG079775-01 | LASMEZAS, CORINNE IDA | VOVA IDA THERAPEUTICS INC, FL | $390,685 | ZRG1 |
| 2022 | Improving an EEG-based neurodiagnostic software platform to detect Alzheimer's Disease in MCI patients1R41AG078039-01A1 | CASELLI, RICHARD J.LUCERO, CHE | SPARK NEURO INC., NY | $299,786 | ZRG1 |
| 2022 | Making Connections Thru Music: A Group Music Therapy-Based Intervention for Persons with Dementia1R42AG076037-01A1 | GORZELLE, GREGGORSULIC-JERAS, SILVIA | HOPEFUL AGING LLC, MA | $299,693 | ZRG1 |
| 2022 | The development of a multifunctional nanoenzyme for AD treatment1R41AG081124-01 | XU, PEISHENG | ACEPRE, LLC, SC | $299,628 | ZRG1 |
| 2022 | PET Probes for Senescence Detection in Brain1R41AG081007-01 | CUI, LINA | SENOTRAC BIOTECHNOLOGY LLC, FL | $293,317 | ZRG1 |
| 2022 | Early detection and monitoring of Alzheimers Disease and Related Dementias using non-semantic linguistic and acoustic features of speech derived from hearing aids1R41AG080977-01 | BISCHOFF, BRIAN JOHN | HEADWATERS INNOVATION, INC., MN | $265,844 | ZRG1 |
| 2022 | AAV-AIBP Therapy for Alzheimer's Disease1R41AG081004-01 | JU, WONKYUKOGAN, YAKOV | RAFT PHARMACEUTICALS, LLC, CA | $247,056 | ZRG1 |
| 2021 | Using Rendever to improve the quality of life of older adults with cognitive impairments in senior living communities and their family members who live at a distance.2R42AG063640-02 | AFIFI, TAMARA DAWNCOLLINS, NANCY LEERAND, KYLE PATRICK | RENDEVER, INC., MA | $1,117,124 | ZRG1 |
| 2021 | Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD2R42AG062130-03 | REINEKE, SEAN | AROMHA, INC., MD | $999,982 | ZRG1 |
| 2021 | Promoting adult hippocampal neurogenesis in Alzheimer's Disease using an antibody-based therapy1R41AG073144-01A1 | VALAT, ANNE | BOLDEN THERAPEUTICS, INC., RI | $500,000 | ZRG1 |
| 2021 | Xenon gas treatment to modulate microglia in neurodegenerative diseases1R41AG073059-01A1 | BUTOVSKY, OLEGILIN, ILYA | GENERAL BIOPHYSICS, LLC, MA | $499,546 | ZRG1 |
| 2021 | An AI-assisted screening platform within a multivariate framework for biomarkers of mild cognitive impairment due to Alzheimer's disease1R41AG073066-01 | CABRERA-DEBUC, DELIAMENDOZA-SANTIESTEBAN, CARLOS E.RAMOS, ALBERTO RAFAEL | ISCREEN 2 PREVENT LLC, FL | $461,215 | ZRG1 |
| 2021 | Development of perivascular space mapping toolset as a diagnostic aid for Alzheimer's disease1R41AG073024-01 | CHOUPAN, JEIRAN | NEUROSCOPE INC., NY | $461,031 | ZRG1 |
| 2021 | Targeting Necroptosis for Neurodegenerative Disease Therapy1R41AG069606-01A1 | KHANNA, MAYPATEK, MARCEL | REGENERIX LLC, AZ | $449,594 | ZRG1 |
| 2021 | 'Novel Shc Blockers as potential Alzheimer's Disease Therapeutics1R41AG076327-01 | CORTOPASSI, GINO A | BUTO CORPORATION, CA | $304,652 | ZRG1 |
| 2021 | Development of a Digital Cognitive Screening Test to detect Mild Cognitive Impairment and Dementia in Clinical Settings.1R41AG074835-01 | MANKODIYA, KUNAL | ECHOWEAR LLC, RI | $300,234 | ZRG1 |
| 2021 | Remote Patient Monitoring of Family Caregivers of Patients with Alzheimer's Disease1R41AG072943-01 | NICOLLA, JONATHAN | PREPPED HEALTH, LLC, NC | $299,782 | ZRG1 |
| 2021 | Developing a widely-useable wearable Circadian Profiling System to assess 24-hour behavioral rhythm disruption in people with dementia and their family caregivers1R41AG069596-01A1 | SMAGULA, STEPHEN F | ACTIVITY RHYTHM SOLUTIONS CORPORATION, PA | $299,526 | ZRG1 |
| 2020 | Nanoparticles for detecting noradrenergic neurons in Alzheimer's Disease1R41AG069539-01 | MOHANKUMAR, PULIYUR | S G ENDOCRINE RESEARCH LLC, GA | $266,683 | ZRG1 |
| 2020 | Development of a tool to examine proteomic pathways in the AD brain1R41AG067855-01 | GUNTHER, ERIK C | PROTEOWISE, INC., CT | $251,944 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.